IPCI.Q Stock Overview
A pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Intellipharmaceutics International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.000001 |
| 52 Week High | CA$0.15 |
| 52 Week Low | CA$0.000001 |
| Beta | 0.56 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPCI.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.6% | -0.4% |
| 1Y | -100.0% | 10.0% | 24.8% |
Return vs Industry: IPCI.Q underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: IPCI.Q underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| IPCI.Q volatility | |
|---|---|
| IPCI.Q Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IPCI.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine IPCI.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Isa Odidi | www.intellipharmaceutics.com |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease.
Intellipharmaceutics International Inc. Fundamentals Summary
| IPCI.Q fundamental statistics | |
|---|---|
| Market cap | US$1.84m |
| Earnings (TTM) | -US$3.17m |
| Revenue (TTM) | US$904.95k |
0.0x
P/S Ratio0.0x
P/E RatioIs IPCI.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCI.Q income statement (TTM) | |
|---|---|
| Revenue | US$904.95k |
| Cost of Revenue | US$475.89k |
| Gross Profit | US$429.06k |
| Other Expenses | US$3.60m |
| Earnings | -US$3.17m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 47.41% |
| Net Profit Margin | -350.72% |
| Debt/Equity Ratio | -16.9% |
How did IPCI.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 04:11 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2023/08/31 |
| Annual Earnings | 2022/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Intellipharmaceutics International Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Raymond Deacon | Brean Capital |
| Jonathan Aschoff | Brean Capital |